Excelsior Biopharma Inc. (TPEX:6496)
Taiwan · Delayed Price · Currency is TWD 26.65
-0.10 (-0.37%)
Aug 7, 2025, 1:26 PM CST
CTI BioPharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | -105.89 | -98.71 | -91.01 | -33.76 | -15.65 | 35.3 | Upgrade |
Depreciation & Amortization | 71.61 | 70.96 | 46.22 | 26.06 | 28.65 | 27.37 | Upgrade |
Other Amortization | - | - | - | - | - | 0.92 | Upgrade |
Loss (Gain) From Sale of Assets | 0.65 | - | - | - | - | -0 | Upgrade |
Loss (Gain) From Sale of Investments | - | - | - | - | 0.21 | -0.03 | Upgrade |
Loss (Gain) on Equity Investments | -0.93 | -0.25 | - | - | - | - | Upgrade |
Stock-Based Compensation | 0.29 | 0.33 | 0.26 | 0.04 | - | - | Upgrade |
Provision & Write-off of Bad Debts | 3.37 | 2.25 | 0.98 | -3.67 | 4.47 | -0.64 | Upgrade |
Other Operating Activities | 3.52 | 2.81 | 6.75 | 0.78 | 5.53 | -1.17 | Upgrade |
Change in Accounts Receivable | -32.92 | -30.53 | -27.17 | 82.26 | -35.87 | 239.47 | Upgrade |
Change in Inventory | -49.28 | -85.65 | -28.7 | 16.02 | 71.88 | 139.88 | Upgrade |
Change in Accounts Payable | -51.3 | 42.43 | -16.92 | -49.79 | -18.52 | 76.57 | Upgrade |
Change in Other Net Operating Assets | 7.7 | -3.44 | -25.15 | -32.46 | 15.13 | 3.15 | Upgrade |
Operating Cash Flow | -153.19 | -99.8 | -134.75 | 5.49 | 55.82 | 520.81 | Upgrade |
Operating Cash Flow Growth | - | - | - | -90.17% | -89.28% | - | Upgrade |
Capital Expenditures | -82.66 | -257.15 | -35.66 | -7.78 | -2.88 | -11.62 | Upgrade |
Sale of Property, Plant & Equipment | 0.68 | - | - | - | - | 0 | Upgrade |
Investment in Securities | -55.5 | -55.5 | 199.74 | -200 | -6.01 | 32.18 | Upgrade |
Other Investing Activities | 5.63 | 5.62 | -17.47 | 8.54 | -1.8 | 6.37 | Upgrade |
Investing Cash Flow | -131.85 | -307.03 | 146.62 | -199.24 | -10.68 | 26.94 | Upgrade |
Short-Term Debt Issued | - | 0.01 | 0.01 | - | - | - | Upgrade |
Long-Term Debt Issued | - | 110 | - | - | - | 300.63 | Upgrade |
Total Debt Issued | 0.01 | 110.01 | 0.01 | - | - | 300.63 | Upgrade |
Short-Term Debt Repaid | - | -0.01 | -0.01 | - | - | - | Upgrade |
Long-Term Debt Repaid | - | -53.98 | -317.23 | -13.73 | -12.64 | -10.45 | Upgrade |
Total Debt Repaid | -53.96 | -53.99 | -317.24 | -13.73 | -12.64 | -10.45 | Upgrade |
Net Debt Issued (Repaid) | -53.95 | 56.02 | -317.23 | -13.73 | -12.64 | 290.18 | Upgrade |
Repurchase of Common Stock | - | - | - | - | -23.74 | - | Upgrade |
Common Dividends Paid | - | - | - | - | -46.67 | -46.67 | Upgrade |
Other Financing Activities | 0.98 | 0.98 | - | - | - | - | Upgrade |
Financing Cash Flow | -52.97 | 56.99 | -317.23 | -13.73 | -83.04 | 243.51 | Upgrade |
Net Cash Flow | -338.01 | -349.84 | -305.36 | -207.49 | -37.9 | 791.26 | Upgrade |
Free Cash Flow | -235.85 | -356.95 | -170.41 | -2.3 | 52.95 | 509.2 | Upgrade |
Free Cash Flow Growth | - | - | - | - | -89.60% | - | Upgrade |
Free Cash Flow Margin | -26.75% | -41.41% | -22.09% | -0.34% | 3.96% | 35.27% | Upgrade |
Free Cash Flow Per Share | -5.11 | -7.74 | -3.71 | -0.05 | 1.14 | 10.34 | Upgrade |
Cash Interest Paid | 8.21 | 7.96 | 1.36 | 0.88 | 1.12 | 1.2 | Upgrade |
Cash Income Tax Paid | 8.11 | 8.36 | 8.38 | 8.28 | 3.46 | 11.07 | Upgrade |
Levered Free Cash Flow | -195.73 | -311.04 | -139.51 | 4.43 | 59.32 | 505.77 | Upgrade |
Unlevered Free Cash Flow | -190.56 | -306.02 | -135.53 | 7.15 | 62.16 | 506.18 | Upgrade |
Change in Net Working Capital | 123.3 | 69.56 | 95.65 | -7.14 | -41.86 | -464.5 | Upgrade |
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.